Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
RESEARCH TOOLSreports
Holding TCRX?
Track your performance easily
TCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.43 - $9.69
Previous Close$5.52
Volume345.31K
Average Volume (3M)365.09K
Market Cap
$292.42M
Enterprise Value$85.81M
Total Cash (Recent Filing)$297.68M
Total Debt (Recent Filing)$91.07M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Nov 06, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding52,973,870
10 Day Avg. Volume197,669
30 Day Avg. Volume365,088
Standard Deviation0.27
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.15
Price to Sales (P/S)23.97
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.03
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$12.67Price Target Upside129.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
TScan Therapeutics News
PremiumCompany Announcements
Leadership Changes and Stockholder Decisions at TScan Therapeutics
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTScan's progress on both heme and solid tumor platforms is favorable with completion of Phase I enrollment and an update on 1-year clinical & translational data expected.
Financial PerformanceTScan has a solid cash runway into 4Q26, providing financial stability and the ability to fund ongoing research and trials.
Therapeutic AdvancementsTScan's multiple xing approach that combines TCR-Ts against multiple targets could be a significant differentiator in the treatment of melanoma.
Bears Say
EarningsReturn on Equity TTM is -65.28%, highlighting current operational losses which could be a concern for potential investors.
Financial PerformanceA high annualized cash burn rate indicates significant ongoing expenses relative to the company's financial resources.
Treatment EffectivenessFirst generation TCR-T have had limited response rates (30-50%) and short durations of response (3-4 months) due to tumor target heterogeneity, HLA loss of heterozygosity and poor TCR-T persistence and exhaustion.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $2.43 and its highest was $9.69 in the past 12 months.
What is TScan Therapeutics’s market cap?
Currently, no data Available
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is 4 days ago.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Aug 12, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.003.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -$0.32.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 48,697,280 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 1.351%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Among the largest hedge funds holding TScan Therapeutics’s share is Baker Bros Advisors LP. It holds TScan Therapeutics’s shares valued at 16M.
---
TScan Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (129.53% Upside)
$12.67 (129.53% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 163.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $895.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
94.36%
12-Months-Change
Fundamentals
Return on Equity
-46.84%
Trailing 12-Months
Asset Growth
18.28%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
---
TCRX Stock 12 Month Forecast
Average Price Target
$12.67
▲(129.53% Upside)
Technical Analysis
Best Analysts Covering TCRX
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+24.42%
reiterated a buy rating 3 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +24.42% per trade.
---